72
Participants
Start Date
June 25, 2009
Primary Completion Date
January 10, 2013
Study Completion Date
November 22, 2016
PF-03084014
10 mg, 50 mg or 100 mg tablets. Patients dosed from 20 mg - 500 mg, twice daily
DIPRTMNT CLIN Scienze RADIOL e Istocitopatologiche, Bologna
Istituto di Ematologia Seragnoli, Bologna
Karmanos Cancer Center / Wayne State University, Detroit
Anschutz Cancer Pavilion, Aurora
University of Colorado Denver CTRC, Aurora
University of Colorado Hospital, Aurora
Massachusetts General Hospital Clinical Laboratory, Boston
Beth Israel Deaconess Medical Center, Boston
Dana Ferber Cancer institute, Boston
The University of Texas MD Anderson Cancer Center, Houston
Lead Sponsor
Pfizer
INDUSTRY